Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

Sharon Anderson, H. G. Rennke, B. M. Brenner

Research output: Contribution to journalArticle

882 Citations (Scopus)

Abstract

Micropuncture and morphologic studies were performed in six groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney. Groups 1 and 4 received no specific therapy. Groups 2 and 5 were treated with the angiotensin I-converting enzyme inhibitor, enalapril, 50 mg/liter, in the drinking water. Groups 3 and 6 were treated with reserpine (5 mg/liter), hydralazine (80 mg/liter), and hydrochlorothiazide (25 mg/liter). All rats were fed standard chow. Groups 1-3 underwent micropuncture study 4 wk after renal ablation. Untreated group 1 rats exhibited systemic hypertension and elevation of the single nephron glomerular filtration rate (SNGFR) due to high average values for the mean glomerular transcapillary hydraulic pressure gradient (Δ̄P̄) and glomerular plasma flow rate (Q(A)). In group 2 rats, treatment with enalapril prevented systemic hypertension and maintained Δ̄P̄ at near-normal levels without significant reduction in SNGFR and Q(A). In contrast, triple drug therapy normalized systemic hypertension, but failed to lower Δ̄P̄ in group 3 rats. Group 4-6 were followed for 12 wk after renal ablation. Untreated group 4 rats demonstrated continuous systemic hypertension, progressive proteinuria, and glomerular structural lesions, including mesangial expansion and frequent areas of segmental sclerosis. In group 5 rats, treatment with enalapril maintained systemic blood pressure at normal levels over the 12-wk period and dramatically limited the development of proteinuria and glomerular lesions. Despite equivalent systemic blood pressure control in group 6 rats, failure of triple drug therapy to control glomerular hypertension was associated with progressive proteinuria and glomerular lesions comparable to those seen in the untreated group 4 rats. Thus, unless glomerular capillary hypertension is corrected, control of systemic blood pressure is insufficient to prevent progressive renal injury in rats with reduced renal mass.

Original languageEnglish (US)
Pages (from-to)1993-2000
Number of pages8
JournalJournal of Clinical Investigation
Volume77
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Enzyme Inhibitors
Hypertension
Kidney
Enalapril
Proteinuria
Therapeutics
Nephrons
Blood Pressure
Glomerular Filtration Rate
Punctures
Drug Therapy
Hydralazine
Hydrochlorothiazide
Reserpine
Sclerosis
Angiotensin-Converting Enzyme Inhibitors
Drinking Water
Infarction
Wistar Rats
Pressure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. / Anderson, Sharon; Rennke, H. G.; Brenner, B. M.

In: Journal of Clinical Investigation, Vol. 77, No. 6, 1986, p. 1993-2000.

Research output: Contribution to journalArticle

@article{2a389535421248c5b10e9801e9f930b5,
title = "Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat",
abstract = "Micropuncture and morphologic studies were performed in six groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney. Groups 1 and 4 received no specific therapy. Groups 2 and 5 were treated with the angiotensin I-converting enzyme inhibitor, enalapril, 50 mg/liter, in the drinking water. Groups 3 and 6 were treated with reserpine (5 mg/liter), hydralazine (80 mg/liter), and hydrochlorothiazide (25 mg/liter). All rats were fed standard chow. Groups 1-3 underwent micropuncture study 4 wk after renal ablation. Untreated group 1 rats exhibited systemic hypertension and elevation of the single nephron glomerular filtration rate (SNGFR) due to high average values for the mean glomerular transcapillary hydraulic pressure gradient (Δ̄P̄) and glomerular plasma flow rate (Q(A)). In group 2 rats, treatment with enalapril prevented systemic hypertension and maintained Δ̄P̄ at near-normal levels without significant reduction in SNGFR and Q(A). In contrast, triple drug therapy normalized systemic hypertension, but failed to lower Δ̄P̄ in group 3 rats. Group 4-6 were followed for 12 wk after renal ablation. Untreated group 4 rats demonstrated continuous systemic hypertension, progressive proteinuria, and glomerular structural lesions, including mesangial expansion and frequent areas of segmental sclerosis. In group 5 rats, treatment with enalapril maintained systemic blood pressure at normal levels over the 12-wk period and dramatically limited the development of proteinuria and glomerular lesions. Despite equivalent systemic blood pressure control in group 6 rats, failure of triple drug therapy to control glomerular hypertension was associated with progressive proteinuria and glomerular lesions comparable to those seen in the untreated group 4 rats. Thus, unless glomerular capillary hypertension is corrected, control of systemic blood pressure is insufficient to prevent progressive renal injury in rats with reduced renal mass.",
author = "Sharon Anderson and Rennke, {H. G.} and Brenner, {B. M.}",
year = "1986",
language = "English (US)",
volume = "77",
pages = "1993--2000",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

AU - Anderson, Sharon

AU - Rennke, H. G.

AU - Brenner, B. M.

PY - 1986

Y1 - 1986

N2 - Micropuncture and morphologic studies were performed in six groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney. Groups 1 and 4 received no specific therapy. Groups 2 and 5 were treated with the angiotensin I-converting enzyme inhibitor, enalapril, 50 mg/liter, in the drinking water. Groups 3 and 6 were treated with reserpine (5 mg/liter), hydralazine (80 mg/liter), and hydrochlorothiazide (25 mg/liter). All rats were fed standard chow. Groups 1-3 underwent micropuncture study 4 wk after renal ablation. Untreated group 1 rats exhibited systemic hypertension and elevation of the single nephron glomerular filtration rate (SNGFR) due to high average values for the mean glomerular transcapillary hydraulic pressure gradient (Δ̄P̄) and glomerular plasma flow rate (Q(A)). In group 2 rats, treatment with enalapril prevented systemic hypertension and maintained Δ̄P̄ at near-normal levels without significant reduction in SNGFR and Q(A). In contrast, triple drug therapy normalized systemic hypertension, but failed to lower Δ̄P̄ in group 3 rats. Group 4-6 were followed for 12 wk after renal ablation. Untreated group 4 rats demonstrated continuous systemic hypertension, progressive proteinuria, and glomerular structural lesions, including mesangial expansion and frequent areas of segmental sclerosis. In group 5 rats, treatment with enalapril maintained systemic blood pressure at normal levels over the 12-wk period and dramatically limited the development of proteinuria and glomerular lesions. Despite equivalent systemic blood pressure control in group 6 rats, failure of triple drug therapy to control glomerular hypertension was associated with progressive proteinuria and glomerular lesions comparable to those seen in the untreated group 4 rats. Thus, unless glomerular capillary hypertension is corrected, control of systemic blood pressure is insufficient to prevent progressive renal injury in rats with reduced renal mass.

AB - Micropuncture and morphologic studies were performed in six groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney. Groups 1 and 4 received no specific therapy. Groups 2 and 5 were treated with the angiotensin I-converting enzyme inhibitor, enalapril, 50 mg/liter, in the drinking water. Groups 3 and 6 were treated with reserpine (5 mg/liter), hydralazine (80 mg/liter), and hydrochlorothiazide (25 mg/liter). All rats were fed standard chow. Groups 1-3 underwent micropuncture study 4 wk after renal ablation. Untreated group 1 rats exhibited systemic hypertension and elevation of the single nephron glomerular filtration rate (SNGFR) due to high average values for the mean glomerular transcapillary hydraulic pressure gradient (Δ̄P̄) and glomerular plasma flow rate (Q(A)). In group 2 rats, treatment with enalapril prevented systemic hypertension and maintained Δ̄P̄ at near-normal levels without significant reduction in SNGFR and Q(A). In contrast, triple drug therapy normalized systemic hypertension, but failed to lower Δ̄P̄ in group 3 rats. Group 4-6 were followed for 12 wk after renal ablation. Untreated group 4 rats demonstrated continuous systemic hypertension, progressive proteinuria, and glomerular structural lesions, including mesangial expansion and frequent areas of segmental sclerosis. In group 5 rats, treatment with enalapril maintained systemic blood pressure at normal levels over the 12-wk period and dramatically limited the development of proteinuria and glomerular lesions. Despite equivalent systemic blood pressure control in group 6 rats, failure of triple drug therapy to control glomerular hypertension was associated with progressive proteinuria and glomerular lesions comparable to those seen in the untreated group 4 rats. Thus, unless glomerular capillary hypertension is corrected, control of systemic blood pressure is insufficient to prevent progressive renal injury in rats with reduced renal mass.

UR - http://www.scopus.com/inward/record.url?scp=0022544541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022544541&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 1993

EP - 2000

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -